Answers are grounded in this paper and cite their sources.
Ductal carcinoma in situ (DCIS) is encountered much more frequently in the screening population compared to the symptomatic setting. The behaviour of DCIS is highly variable and this presents difficulties in choosing appropriate treatment strategies for individual cases. This review discusses the current data on the frequency and rate of progression of DCIS, the value and limitations of clinicopathological and biological variables in predicting disease behaviour and suggests strategies to develop more robust means of predicting progression of DCIS.
No takes yet. Share an insight, caveat, or question.
J. Louise Jones (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: